Q-omics provides the consensus-scored DIMT1 profile across patient tissues and cancer cell-line models. DIMT1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, DIMT1 is differentially expressed in 12, with the highest sampling consensus in LIHC. Additionally, DIMT1 protein abundance shows 23,388 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRP, LIHC, and GBM as cancer lineages where DIMT1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DIMT1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DIMT1 survival associations across molecular data types. DIMT1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (2) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DIMT1 RNA expression–survival associations across cancer types. High DIMT1 expression shows unfavorable associations in KIRP, KICH, KIRC, LIHC and UVM, but favorable associations in READ. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRP as the clearest survival context for DIMT1 RNA expression.
This table summarizes DIMT1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in LIHC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for DIMT1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DIMT1 shows lower tumor expression in THCA and higher tumor expression in LIHC, KIRP, COAD, KIRC and READ. The LIHC box plot shows higher DIMT1 RNA expression in tumor versus normal tissue (log2 FC = +1.105, t-test p < 0.001).
This table shows molecular features associated with DIMT1 in patient tissues and cancer cell lines. In patient samples, DIMT1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, DIMT1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and UPPER_AERODIGESTIVE_TRACT.
